该项目2024年9月开工建设，总投资约1.32亿元，占地面积8116.89平方米，总建筑面积21005.74平方 米，规划建设地下一层、地上五层，涵盖158个农贸市场摊位、商业商场、地下停车场及室外配套工 程，旨在打造集智慧农贸、主题商业、休闲时光、时尚运动、美食服务于一体的综合性农贸市场。项目 投入使用后，将为周边居民提供便利的购物、休闲、娱乐和美食服务，成为社区综合服务的新地标。 重点项目全力推进 奋力冲刺一季度"开门红" "再过一阵子，我们就可以就近买菜啦！"近日，看着琼海市文坡社区农贸市场室内外施工项目一派热火 朝天的景象，附近居民老陈开心地说。据了解，文坡社区农贸市场及配套工程项目已进入收尾冲刺阶 段，总体施工进度已完成90%以上，预计本月底全部完工并达到竣工验收条件，春节前投入运营。 "待这座新桥通车后，就不用担心汛期会出现漫水阻断交通，让人'无路可走'的情况了。"在万泉镇文曲 新桥建设工程项目现场，看着挖掘机、压路机等机械设备不停地作业，现场工人各司其职，居民吴女士 充满了期待。 据了解，新桥桥梁长度为106米，桥面宽度为6米人行道和16米车行道，总宽度为22米，预计今年春节前 实现功能性通车。 ...

IBTROZI (Taletrectinib) - IBTROZI is a next-generation ROS1 inhibitor approved for advanced ROS1+ NSCLC in the U S, Japan, and China[3] - The U S FDA approved IBTROZI on June 11, 2025[117, 120] - Since its U S launch, IBTROZI has achieved 432 new patient starts[16, 20, 120] - IBTROZI has a theoretical maximum gross market opportunity of approximately $4 billion[16] - Median Duration of Response (DOR) in TKI-naïve patients reached 50 months[24, 25] - Nuvation Bio entered an exclusive licensing agreement with Eisai for IBTROZI in Europe and additional countries, receiving up to ~$230 million in cash consideration[6] Safusidenib - Safusidenib is a potentially best-in-class mIDH1 inhibitor being evaluated in a pivotal study for high-grade and high-risk IDH1-mutant glioma[3, 4, 118, 120] - A Phase 1 study of Safusidenib in high-grade IDH1-mutant glioma showed a 17% confirmed objective response rate (cORR), including 2 complete responses (CRs)[83, 84] - A Phase 2 study of Safusidenib in low-grade IDH1-mutant glioma showed a 24-month progression-free survival (PFS) rate of 88%[71, 83, 84] Financial Status - Nuvation Bio has a robust pro forma cash balance of approximately $589 million, expected to provide a path to profitability without needing additional funding[3, 119]

Core Insights - Vorasidenib, the world's first dual-target IDH inhibitor, has been approved for clinical use in Beijing to treat patients with IDH-mutant diffuse gliomas, enhancing treatment options for this patient group [1][2] - The drug is designed to penetrate the blood-brain barrier and specifically targets IDH1 and IDH2 mutations, marking a significant breakthrough in the treatment of low-grade gliomas [2] - Vorasidenib's introduction in Beijing is facilitated by an innovative policy that accelerates the approval of urgently needed imported drugs, significantly reducing patient wait times for new therapies [3] Group 1 - Vorasidenib is now available in designated medical institutions in Beijing, with initial treatments taking place at major hospitals [1] - The drug addresses the high mortality and recurrence rates associated with IDH-mutant diffuse gliomas, where over 90% of patients experience recurrence despite current treatment options [1] - The median age of onset for patients with IDH-mutant diffuse gliomas is around 40 years, with many facing significant physical and psychological challenges post-surgery [1] Group 2 - Vorasidenib has received approvals in multiple countries, including the US, Canada, Australia, and others, with its introduction in Beijing being part of a broader strategy to enhance access to innovative treatments [3] - The 2024 NCCN guidelines and the Chinese Anti-Cancer Association's updated guidelines now recommend IDH inhibitors for postoperative adjuvant therapy in patients with IDH-mutant gliomas [2] - The inclusion of Vorasidenib in the Beijing Universal Health Insurance special drug list enhances patient access to this treatment, improving their overall treatment experience [3]